AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04774562 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy (PT) Program
Description: Physiotherapy (PT): Breathing exercises, positioning, hip range of motion and strengthening exercises, and information about walking and ambulation.
Study NCT01475825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen sodium 200 mg
Description: Subcutaneous mipomersen 200 mg once weekly
Study NCT03344731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive evaluation
Description: Cognitive task
Study NCT01475825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vehicle for subcutaneous injection.
Study NCT03344731 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive brain stimulation
Description: Transcranial Magnetic Stimulation (TMS)
Study NCT01475825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen sodium 70 mg
Description: Subcutaneous mipomersen 70 mg thrice weekly
Study NCT01730573 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interscalene block
Description: This arm patients will receive inter scalene block which will be ultrasound and nerve stimulator guided.
Study NCT01730573 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprascapular and Axillary nerve block
Description: This arm patients will receive Suprascapular and axillary nerve blocks which will be ultrasound guided and nerve stimulator guided.
Study NCT02969226 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Once daily screening
Description: RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
Study NCT02602847 — intervention group
Intervention type: BIOLOGICAL
Intervention: cccDNA assay on liver biopsy
Description: cccDNA assay will be performed on liver biopsies at different times : During transplantation : Liver biopsy of explant and graft and virological biology Between M1 to M3 after transplantation : Liver biopsy between 1 to 3 months after transplantation M12 : Liver biopsy 12 months after transplantation
Study NCT01002482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGAO-based Glucose Control
Description: Use of a clinical computerized decision-support system named CGAOtm designed to achieve tight glucose control in various ICU settings, and fine-tuned to reduce glucose variability without increasing the incidence of severe hypoglycemia or nurse workload.~CGAOtm is based on explicit replicable recommendations following each blood glucose measurement for insulin rates and time to next measurement, and reminders, alerts, graphic tools, trends, and individual on-line data aimed at increasing confidence of the nursing staff in the computer protocol and giving care staff a method for controlling the process during the whole ICU stay, according to a human-in-the-loop approach.~The algorithm used in the CGAOtm software for the calculation of the recommended insulin rates derived from a PID (Proportional-integral-derivative) controller, a generic control loop feedback mechanism widely used in industrial control.
Study NCT01002482 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard-Care Glucose Control
Description: Patients in the control group will receive conventional insulin therapy using the usual care protocol of each participating centre (already used in the centre before the beginning of the trial and targeting blood glucose levels inferior to 180 mg/dl).
Study NCT01728948 — intervention group
Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: treatment (including dose, duration, modification) decided by the investigator
Study NCT03732690 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet HP
Description: 2000kcal for men 1800 kcal for women. Food boxes (HP pre-cooked meals and meat/chicken/fish portions, HP breads and snacks) will be provided to the participants throughout the study reaching 40-50% of their prescribed daily energy intake for 6 days per week. In total 932 kcal are provided through this food boxes (54g of carbohydrate, 101g of protein, 34,6g of fat). The rest of the daily food intake will be guided by a dietician with a list of recommended high protein foods.~Subjects are required to keep food diaries three days a week and will also have weekly contact with a dietician.
Study NCT03732690 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet LP
Description: 2000kcal for men 1800 kcal for women. Food boxes (LP pre-cooked meals, LP breads and snacks) will be provided to the participants throughout the study
Study NCT02591849 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperglycemic clamp
Study NCT02591849 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hyperglycemic clamp
Study NCT03294473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: R/R - Autodialers
Description: Investigators will send out flu vaccine reminder recall notices via autodialer message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
Study NCT03294473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: R/R - Texting
Description: Investigators will send out flu vaccine reminder recall notices via text message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
Study NCT02969226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Twice daily screening
Description: In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
Study NCT02969226 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Twice daily screening
Description: In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
Study NCT02969226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PS SBTs
Description: Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS >0 and =\< 8 cm H2O with PEEP>0 and =\< 5 cm H2O
Study NCT02969226 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PS SBTs
Description: Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS >0 and =\< 8 cm H2O with PEEP>0 and =\< 5 cm H2O
Study NCT02969226 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T-piece SBTs
Description: Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece (off the ventilator)
Study NCT03294473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: R/R - mailed postcard
Description: Investigators will send out flu vaccine reminder recall notices via mailed postcards to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
Study NCT00130273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Managed problem solving
Description: Participants in the managed problem solving group will have four study visits and will receive three phone calls for the first 3 months of the study, and one phone call every month for the following 9 months. At each study visit, participants will identify barriers to adherence. During the phone calls, participants will be asked about any steps they have taken to improve their adherence. A medication event monitoring system (MEMS) will be used to assess participants' treatment adherence. MEMS uses microelectronic monitors on the caps of medication bottles to record the timing and frequency of bottle openings. Participants whose adherence has decreased or remained the same at the end of 12 months will be evaluated for regimen changes. Blood collection at the beginning and end of the study will be used to measure viral load and CD4 count.
Study NCT01604798 — intervention group
Intervention type: OTHER
Intervention: Serum proteomics
Description: magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry
Study NCT04509232 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: Group A~* Excavation of soft carious dentin will be done to minimize the staining.~* The selected teeth should be cleaned, dried and isolated. Vaselline should be applied to surrounding soft tissues to avoid their staining.-~* 38% Silver diamine fluoride will be applied to carious lesions by microbrush~* Apply gentle flow of air until medicament is dry, Try to keep isolated for three minutes,remove excess SDF with cotton pellet to decrease systemic absorption.~After silver diamine fluoride application Assessement of parental acceptance to staining will be done though a 5 point likert scale For anterior and posterior teeth separately .
Study NCT04509232 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride and glass ionomer
Description: * 38% Silver diamine fluoride will be applied by the same protocol as in group A Then Glass Ionomer restoration is applied~* Parental acceptance to staining will be assessed thought 5 point likert scale after application of SDF and once more after application of Glass Ionomer restoration.
Study NCT01881737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone
Description: With Baseline serving as approximately day 1, twice daily intake of orally administered pregnenolone will occur on a schedule consisting of an up-titration followed by a down-titration as described below.~Week 1 and 2: 100 mg~Week 3 and 4: 200 mg~Week 5 and 6: 300 mg~Week 7 and 8: 400 mg~Week 9 -12: 500 mg~At the end of Week 12, pregnenolone was decreased by 50 mg twice a day every 3 days until it was discontinued.~If the participant is unable to tolerate a specific dose then he/she will be maintained at the highest tolerated dose until down titration occurs.
Study NCT04045145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crinecerfont
Description: Crinecerfont administered orally for 14 consecutive days.
Study NCT02920047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan/Amlodipine
Description: Treatment B
Study NCT00130273 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Participants will receive standard of care for 12 months.
Study NCT01361334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg QD p.o.
Study NCT00929019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cells electroporated with mRNA
Description: Autologous mature monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
Study NCT03675724 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: Flavonoid Family
Study NCT03675724 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo
Study NCT02338921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100mg qd per oral during 24months~compared with other treatment groups
Study NCT02338921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 10mg qd per oral during 24months~compared with other treatment groups
Study NCT02338921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lobeglitazone
Description: 0.5mg qd per oral during 24months~compared with other treatment groups
Study NCT02338921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepirde
Study NCT02338921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT05868018 — intervention group
Intervention type: BEHAVIORAL
Intervention: Education
Description: This was an observational study of changes in evidence based confidence and behavior across 4 physical therapy programs. Students received their typical physical therapy education and we measured changes in evidence based practice confidence and behaviors across programs throughout the curriculum.
Study NCT01658488 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-fortified rice
Description: Consumption of 2 servings of Non-fortified rice per day in women with iron deficiency anemia and measure serum iron and transferrin at baseline and end of study.
Study NCT01658488 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Iron-fortified Rice
Description: Consumption of 2 servings of Iron-fortified rice per day in women with iron deficiency anemia and measure serum iron and transferrin at baseline and end of study.
Study NCT03613584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Von Willebrand Factor
Description: Bolus and continuous infusion of the Investigational Medicinal Product (IMP) during extracorporeal membrane oxygenation (ECMO)
Study NCT03613584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Bolus and continuous infusion of the Investigational Medicinal Product (IMP) during extracorporeal membrane oxygenation (ECMO)
Study NCT02692235 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carnitine
Description: 1500 mg/d l-carnitine-l-tartrate
Study NCT02692235 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: isonitrogenous
Study NCT03177564 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Protective ventilation 1
Description: Low tidal volume, high inspired oygen fraction (FiO2) and recruitment maneuver.
Study NCT03177564 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Protective ventilation 2
Description: Low tidal volume, PEEP, moderate inspired oygen fraction (FiO2) and recruitment maneuver.
Study NCT03177564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Driving Pressure Limited Ventilation
Description: Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 3 to 10 cmH2O during one-lung ventilation and a FiO2 of 60%
Study NCT05436626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early BDI reconstruction without abdominal sepsis control
Description: BDI reconstruction within 6 weeks after the injury without abdominal sepsis control
Study NCT05436626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early BDI reconstruction with abdominal sepsis control
Description: BDI reconstruction within 6 weeks after the injury with abdominal sepsis control
Study NCT05436626 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed reconstruction
Description: BDI reconstruction after 6 weeks after the injury
Study NCT01828437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxine plus prednisolone
Study NCT01828437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Study NCT02725996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: Adjuvant adoptive immune therapy using NK cell 4 times
Study NCT02725996 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Curative therapy
Description: Patients who had undergone curative treatment(surgical resection or radiofrequency ablation for HCC of pretreatment clinical stage I or II were eligible for this study with no adjuvant treatment
Study NCT02725996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Curative therapy
Description: Patients who had undergone curative treatment(surgical resection or radiofrequency ablation for HCC of pretreatment clinical stage I or II were eligible for this study with no adjuvant treatment
Study NCT02407496 — intervention group
Intervention type: OTHER
Intervention: Behavioral assessment and NAT EEG tests
Description: Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.
Study NCT03447444 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: music and physical activity
Description: This feasibility study focus on promoting a combination of music therapy and physical activity with the primary goal to describe the influence on restlessness, irritability, and aggression in persons with severe stage of dementia with a mixture of symptoms including frontal lobe problems in institutional care. A secondary goal is to investigate the treatment fidelity.
Study NCT00844870 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stabilization training
Description: training of arm function with the trunk stabilized
Study NCT00844870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: auditory training group
Description: response to an auditory signal
Study NCT03937700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPWalker Robotic Exoskeleton
Description: The CPWalker rehabilitation platform is a robotic device composed by an exoskeleton linked to a walker that provides support and balance to a child during overground training. The device is able to implement user's partial body weight support (PBWS) and allows the adaptation of exercises to the patient's capabilities by means of individual controllers for each joint, which increases the modularity of the system. Each joint of the CPWalker can operate in a range of modes with varied levels of robotic assistance or resistance
Study NCT00432159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical TDR
Description: Cervical total disc replacement using a DISCOVER Artificial Cervical Disc.
Study NCT02718001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards EVOQUE Eos Mitral Valve Replacement System
Description: Replacement of the mitral valve through a transcatheter approach
Study NCT00432159 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ACDF with plate
Description: Anterior cervical discectomy followed by insertion of allograft spacer and placement of an anterior plate.
Study NCT02643771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full Mouth Scaling and Root Planing
Description: This procedure was performed as described by Quirynen et al. 2005 with some modifications
Study NCT03344731 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive brain stimulation
Description: Transcranial Magnetic Stimulation (TMS)
Study NCT02743403 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurodyn Portable activeTENS, IBRAMED®
Description: Randomization and secret Allocation active TENS (GI / n = 27)
Study NCT02214381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myocet
Study NCT02743403 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neurodyn Portable activeTENS, IBRAMED®
Description: Randomization and secret Allocation active TENS (GI / n = 27)
Study NCT02214381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT02214381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT01304524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX 3100
Description: 1ml of VGX-3100 delivered IM followed by electroporation at Day 0, Week 4 and Week 12.
Study NCT01304524 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1ml of placebo delivered IM followed by electroporation at Day 0, Week 4 and Week 12.
Study NCT01304524 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CELLECTRA™-5P
Description: CELLECTRA™-5P is used for electroporation following IM delivery of VGX 3100 or placebo on Day 0, Week 4 and Week 12.
Study NCT01304524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA™-5P
Description: CELLECTRA™-5P is used for electroporation following IM delivery of VGX 3100 or placebo on Day 0, Week 4 and Week 12.
Study NCT04006795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serum
Description: Participants will be topically applied adhesive patch containing developmental serum
Study NCT04006795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lotion
Description: Participants will be topically applied adhesive patch containing developmental lotion
Study NCT04006795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cream
Description: Participants will be topically applied adhesive patch containing developmental cream
Study NCT02743403 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurodyn Portable placeboTENS, IBRAMED®
Description: Randomization and secret Allocation placebo TENS (GII / n = 27)
Study NCT02743403 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neurodyn Portable placeboTENS, IBRAMED®
Description: Randomization and secret Allocation placebo TENS (GII / n = 27)
Study NCT04006795 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Participants will be topically applied adhesive patch containing normal saline
Study NCT03452111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nestorone + Testosterone Combination Gel
Description: The combined gel is a transdermal treatment that will be applied daily for 52 weeks to a male subject's arms and shoulders. The formulation will be a hydro alcoholic gel. About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume.